Loading...
``
Dysesthesia, an unpleasant sensation that is perceived on or under the skin, can occur spontaneously or in response to mild cutaneous stimuli. In four recent placebo-controlled clinical trials, dysesthesia was reported as a side effect of the GLP-1 agonist semaglutide.
The incidence of dysesthesia in these studies was as follows:
5% with 25 mg of oral semaglutide daily 1
13% with 50 mg of oral semaglutide daily 2
23% and 6% with injected semaglutide at weekly doses of 7.2 mg and 2.4 mg, respectively 3 — and 19% and 5% in a separate study of the same two doses4
The first three studies involved patients with obesity but not diabetes; the fourth involved patients with both obesity and diabetes. The incidence of dysesthesia in placebo recipients was…